Go Pro
OTCMKTS:BSPM

Biostar Pharmaceuticals (BSPM) Stock Price, News & Analysis

Biostar Pharmaceuticals logo

About Biostar Pharmaceuticals Stock (OTCMKTS:BSPM)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biostar Pharmaceuticals, Inc. (OTCMKTS: BSPM) is a development-stage biopharmaceutical company focused on acquiring, licensing and advancing novel therapeutic candidates in oncology and metabolic disease. The company’s primary business activity involves identifying proprietary small-molecule and biologic compounds through collaborations with academic institutions, research organizations and biotech partners. Biostar aims to leverage cost-effective development pathways to progress its pipeline from preclinical research into early-stage clinical trials.

Through strategic licensing agreements, Biostar Pharmaceuticals builds a diversified portfolio of drug candidates targeting solid tumors, hematological malignancies and metabolic disorders. The company’s R&D strategy emphasizes preclinical validation, pharmacology studies and formulation development, with the goal of advancing select assets toward Phase 1 and Phase 2 clinical evaluations. By focusing on niche indications and leveraging external expertise, Biostar seeks to optimize capital efficiency and position its programs for potential out-licensing or co-development partnerships.

Biostar serves global markets via collaborative networks rather than direct commercial operations, enabling the company to tap into specialized research capabilities and manufacturing resources worldwide. While specific leadership details are not broadly publicized, the management team comprises professionals with backgrounds in drug discovery, regulatory affairs and business development. Biostar continues to explore new licensing opportunities and strategic alliances to expand its pipeline and move its therapeutic programs forward.

AI Generated. May Contain Errors.

Receive BSPM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biostar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BSPM Stock News Headlines

Beijing Biostar Pharmaceuticals Co. Ltd.
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.tc pixel
Biostar Pharmaceuticals Inc (BSPM)
Biostar Pharmaceuticals, Inc. (BSPM)
See More Headlines

BSPM Stock Analysis - Frequently Asked Questions

Biostar Pharmaceuticals, Inc. (OTCMKTS:BSPM) announced its earnings results on Wednesday, November, 15th. The company reported ($0.50) earnings per share (EPS) for the quarter.

Shares of BSPM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biostar Pharmaceuticals investors own include Cellectar Biosciences (CLRB), HudBay Minerals (HBM), Baytex Energy (BTE), Cyclacel Pharmaceuticals (CYCC) and

Company Calendar

Last Earnings
11/15/2017
Today
8/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:BSPM
CIK
N/A
Fax
N/A
Employees
200
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
75.18
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (OTCMKTS:BSPM) was last updated on 8/18/2026 by MarketBeat.com Staff.
From Our Partners